carvedilol has been researched along with Innate Inflammatory Response in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol and N-acetyl cysteine (NAC) combination decreases inflammation, oxidative stress, and postoperative atrial fibrillation (POAF) rates more than metoprolol or carvedilol." | 9.19 | Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs carvedilol or carvedilol plus N-acetyl cysteine treatment. ( Akcay, S; Ceyhan, BM; Dogan, A; Erdogan, D; Icli, A; Okutan, H; Ozaydin, M; Peker, O; Sutcu, R; Uysal, BA; Varol, E; Yucel, H, 2014) |
| " The current study aimed to investigate the effectiveness of carvedilol (CV), Acetovanillone (ACET), and their combination for ameliorating cadmium (Cd)-induced oxidative stress, inflammation, and necroptosis." | 8.31 | Acetovanillone augmented the cardioprotective effect of carvedilol against cadmium-induced heart injury via suppression of oxidative stress and inflammation signaling pathways. ( Ahmed, LK; Ali, FEM; Bakr, AG; El-Shoura, EAM; Hassanein, EHM, 2023) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 7.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "Increased inflammatory activation observed only in heart failure patients not improving left-ventricular function after carvedilol may indicate that inflammation, either as a direct cause or as a consequence, is associated with progressive ventricular dysfunction." | 7.79 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. ( Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R, 2013) |
| "Carvedilol (CAR) is a β-blocker used to treat high blood pressure and heart failure." | 5.51 | Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. ( Yang, JJ; Zhang, HS; Zhang, QL, 2019) |
| "Carvedilol is a β-blocker used to treat high blood pressure and heart failure." | 5.46 | Carvedilol abrogates hypoxia-induced oxidative stress and neuroinflammation in microglial BV2 cells. ( Fu, Z; Gao, X; Wu, B; Xu, G; Zhang, Z, 2017) |
| "Carvedilol was orally administered at a dose of 10 mg/kg for 2 weeks, and cisplatin was given as a single intraperitoneal injection of 10 mg/kg on the 12th day to induce toxicity." | 5.43 | Carvedilol alleviates testicular and spermatological damage induced by cisplatin in rats via modulation of oxidative stress and inflammation. ( Abd El-Raouf, OM; Abdelkader, NF; Eid, AH; El-Denshary, ES; Fawzy, HM, 2016) |
| "Carvedilol pretreatment significantly attenuated the potassium dichromate-induced DNA damage, decreased the p53, Bax and cleaved caspase-3 expression and increased the Bcl-2 expression." | 5.40 | Chromium-induced nephrotoxicity and ameliorative effect of carvedilol in rats: Involvement of oxidative stress, apoptosis and inflammation. ( Bijargi, SR; Koneru, M; Kota, A; Sahu, BD; Sistla, R, 2014) |
| "Carvedilol and N-acetyl cysteine (NAC) combination decreases inflammation, oxidative stress, and postoperative atrial fibrillation (POAF) rates more than metoprolol or carvedilol." | 5.19 | Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs carvedilol or carvedilol plus N-acetyl cysteine treatment. ( Akcay, S; Ceyhan, BM; Dogan, A; Erdogan, D; Icli, A; Okutan, H; Ozaydin, M; Peker, O; Sutcu, R; Uysal, BA; Varol, E; Yucel, H, 2014) |
| " The current study aimed to investigate the effectiveness of carvedilol (CV), Acetovanillone (ACET), and their combination for ameliorating cadmium (Cd)-induced oxidative stress, inflammation, and necroptosis." | 4.31 | Acetovanillone augmented the cardioprotective effect of carvedilol against cadmium-induced heart injury via suppression of oxidative stress and inflammation signaling pathways. ( Ahmed, LK; Ali, FEM; Bakr, AG; El-Shoura, EAM; Hassanein, EHM, 2023) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 3.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "We tested the non-selective β-blockers, carvedilol and nadolol, in house dust mite (HDM) driven murine asthma models where drugs were administered both pre- and post-development of the asthma phenotype." | 3.85 | Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype. ( Bond, RA; Eikenburg, DC; Joshi, R; Kim, H; Knoll, BJ; Valdez, D, 2017) |
| "Increased inflammatory activation observed only in heart failure patients not improving left-ventricular function after carvedilol may indicate that inflammation, either as a direct cause or as a consequence, is associated with progressive ventricular dysfunction." | 3.79 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. ( Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R, 2013) |
| " The aim of study was to assess the correlation between the therapeutic efficacy of carvedilol and markers of endothelial dysfunction and systemic inflammation in patients with liver cirrhosis and portal hypertension." | 3.73 | Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. ( Bruha, R; Dousa, M; Jachymova, M; Kalab, M; Lenicek, M; Marecek, Z; Petrtyl, J; Svestka, T; Urbanek, P; Vitek, L; Zelenka, J, 2006) |
| "Inflammation is one of the main mechanisms of pancreatic β-cell damage and the development of type 1 diabetes (T1D)." | 1.62 | Carvedilol prevents pancreatic β-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-κB, COX-2, iNOS and oxidative stress. ( Amirshahrokhi, K; Zohouri, A, 2021) |
| "Carvedilol (CAR) is a β-blocker used to treat high blood pressure and heart failure." | 1.51 | Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. ( Yang, JJ; Zhang, HS; Zhang, QL, 2019) |
| "Carvedilol is a β-blocker used to treat high blood pressure and heart failure." | 1.46 | Carvedilol abrogates hypoxia-induced oxidative stress and neuroinflammation in microglial BV2 cells. ( Fu, Z; Gao, X; Wu, B; Xu, G; Zhang, Z, 2017) |
| "Carvedilol was orally administered at a dose of 10 mg/kg for 2 weeks, and cisplatin was given as a single intraperitoneal injection of 10 mg/kg on the 12th day to induce toxicity." | 1.43 | Carvedilol alleviates testicular and spermatological damage induced by cisplatin in rats via modulation of oxidative stress and inflammation. ( Abd El-Raouf, OM; Abdelkader, NF; Eid, AH; El-Denshary, ES; Fawzy, HM, 2016) |
| "Recent findings from septic acute renal injury studies have implicated the mitochondrion as an important factor in kidney injury, and that increased sympathetic nerve activity may contribute to the induction of organ failure." | 1.42 | Low-dose carvedilol protects against acute septic renal injury in rats during the early and late phases. ( Abdel Kawy, HS, 2015) |
| "Carvedilol pretreatment significantly attenuated the potassium dichromate-induced DNA damage, decreased the p53, Bax and cleaved caspase-3 expression and increased the Bcl-2 expression." | 1.40 | Chromium-induced nephrotoxicity and ameliorative effect of carvedilol in rats: Involvement of oxidative stress, apoptosis and inflammation. ( Bijargi, SR; Koneru, M; Kota, A; Sahu, BD; Sistla, R, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Hassanein, EHM | 1 |
| Bakr, AG | 1 |
| El-Shoura, EAM | 1 |
| Ahmed, LK | 1 |
| Ali, FEM | 1 |
| Amirshahrokhi, K | 1 |
| Zohouri, A | 1 |
| Joshi, R | 1 |
| Valdez, D | 1 |
| Kim, H | 1 |
| Eikenburg, DC | 1 |
| Knoll, BJ | 1 |
| Bond, RA | 1 |
| Gao, X | 1 |
| Wu, B | 1 |
| Fu, Z | 1 |
| Zhang, Z | 1 |
| Xu, G | 1 |
| Skrzypiec-Spring, M | 1 |
| Haczkiewicz, K | 1 |
| Sapa, A | 1 |
| Piasecki, T | 1 |
| Kwiatkowska, J | 1 |
| Ceremuga, I | 1 |
| Wozniak, M | 1 |
| Biczysko, W | 1 |
| Kobierzycki, C | 1 |
| Dziegiel, P | 1 |
| Podhorska-Okolow, M | 1 |
| Szelag, A | 1 |
| Guang-Yi, C | 1 |
| Li-Sha, G | 1 |
| Yue-Chun, L | 1 |
| Zhang, QL | 1 |
| Yang, JJ | 1 |
| Zhang, HS | 1 |
| Grandinetti, V | 1 |
| Carlos, FP | 1 |
| Antonio, EL | 1 |
| de Oliveira, HA | 1 |
| Dos Santos, LFN | 1 |
| Yoshizaki, A | 1 |
| Mansano, BSDM | 1 |
| Silva, FA | 1 |
| Porte, LA | 1 |
| Albuquerque-Pontes, GM | 1 |
| de Carvalho, PTC | 1 |
| Manchini, MT | 1 |
| Leal-Junior, EC | 1 |
| Tucci, PJF | 1 |
| Serra, AJ | 1 |
| Kim, EJ | 1 |
| Song, WH | 1 |
| Lee, JU | 1 |
| Shin, MS | 1 |
| Lee, S | 1 |
| Kim, BO | 1 |
| Hong, KS | 1 |
| Han, SW | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Ozaydin, M | 1 |
| Peker, O | 1 |
| Erdogan, D | 1 |
| Akcay, S | 1 |
| Yucel, H | 1 |
| Icli, A | 1 |
| Ceyhan, BM | 1 |
| Sutcu, R | 1 |
| Uysal, BA | 1 |
| Varol, E | 1 |
| Dogan, A | 1 |
| Okutan, H | 1 |
| Sahu, BD | 1 |
| Koneru, M | 1 |
| Bijargi, SR | 1 |
| Kota, A | 1 |
| Sistla, R | 1 |
| Abdel Kawy, HS | 1 |
| Eid, AH | 1 |
| Abdelkader, NF | 1 |
| Abd El-Raouf, OM | 1 |
| Fawzy, HM | 1 |
| El-Denshary, ES | 1 |
| Fragasso, G | 1 |
| Spoladore, R | 1 |
| Maranta, F | 1 |
| Corti, A | 1 |
| Lattuada, G | 1 |
| Colombo, B | 1 |
| Locatelli, M | 1 |
| Salerno, A | 1 |
| Calori, G | 1 |
| Briceno, L | 1 |
| Alfieri, AB | 1 |
| Perseghin, G | 1 |
| Margonato, A | 1 |
| Cheng, SM | 1 |
| Yang, SP | 1 |
| Ho, LJ | 1 |
| Tsao, TP | 1 |
| Chang, DM | 1 |
| Lai, JH | 1 |
| Vita, JA | 1 |
| Calò, LA | 1 |
| Semplicini, A | 1 |
| Davis, PA | 1 |
| Bruha, R | 1 |
| Vitek, L | 1 |
| Petrtyl, J | 1 |
| Lenicek, M | 1 |
| Urbanek, P | 1 |
| Zelenka, J | 1 |
| Jachymova, M | 1 |
| Svestka, T | 1 |
| Kalab, M | 1 |
| Dousa, M | 1 |
| Marecek, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans[NCT03016351] | 140 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carvedilol and Innate Inflammatory Response
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
Role of Heart Rate Reduction in the Management of Myocarditis.
Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Agents; Carvedilol; Heart Rate; Humans; Inflamm | 2018 |
Nitric oxide and vascular reactivity in African American patients with hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Black or African American; Brachial Artery; Carba | 2003 |
2 trials available for carvedilol and Innate Inflammatory Response
| Article | Year |
|---|---|
Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; C | 2014 |
Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs carvedilol or carvedilol plus N-acetyl cysteine treatment.
Topics: Acetylcysteine; Aged; Antihypertensive Agents; Atrial Fibrillation; Carbazoles; Cardiac Surgical Pro | 2014 |
14 other studies available for carvedilol and Innate Inflammatory Response
| Article | Year |
|---|---|
Acetovanillone augmented the cardioprotective effect of carvedilol against cadmium-induced heart injury via suppression of oxidative stress and inflammation signaling pathways.
Topics: Animals; Antioxidants; Cadmium; Carvedilol; Heart Injuries; Inflammation; NADPH Oxidases; NF-E2-Rela | 2023 |
Carvedilol prevents pancreatic β-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-κB, COX-2, iNOS and oxidative stress.
Topics: Animals; Blood Glucose; Body Weight; Carvedilol; Cyclooxygenase 2; Cytokines; Diabetes Mellitus, Typ | 2021 |
Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.
Topics: Adrenergic beta-Antagonists; Animals; Asthma; Carbazoles; Carvedilol; Disease Models, Animal; Inflam | 2017 |
Carvedilol abrogates hypoxia-induced oxidative stress and neuroinflammation in microglial BV2 cells.
Topics: Animals; Carbazoles; Carvedilol; Cell Hypoxia; Cell Line; Cell Survival; Dose-Response Relationship, | 2017 |
Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; Carbazoles; Carvedilol; Di | 2018 |
Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy.
Topics: Abietanes; Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Autophagy; Cardiotoxicity; | 2019 |
Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats.
Topics: Animals; Carvedilol; Catalase; Disease Models, Animal; Echocardiography; Female; Heart Failure; Hemo | 2019 |
Chromium-induced nephrotoxicity and ameliorative effect of carvedilol in rats: Involvement of oxidative stress, apoptosis and inflammation.
Topics: Acute Kidney Injury; Animals; Antioxidants; Apoptosis; Carbazoles; Carvedilol; Chromium; Inflammatio | 2014 |
Low-dose carvedilol protects against acute septic renal injury in rats during the early and late phases.
Topics: Acute Kidney Injury; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Glutathione; Inflammat | 2015 |
Carvedilol alleviates testicular and spermatological damage induced by cisplatin in rats via modulation of oxidative stress and inflammation.
Topics: Animals; Carbazoles; Carvedilol; Cisplatin; Inflammation; Inflammation Mediators; Male; Oxidative St | 2016 |
Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cohort Studies; Cytokines; Echocardiograp | 2013 |
Carvedilol modulates in-vitro granulocyte-macrophage colony-stimulating factor-induced interleukin-10 production in U937 cells and human monocytes.
Topics: Adrenergic beta-Antagonists; Apoptosis; Carbazoles; Carvedilol; DNA Fragmentation; Dose-Response Rel | 2003 |
Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients.
Topics: Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Humans; Hypertension; Inflammation; O | 2005 |
Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; E-Selectin; Endothelium, Vascular; | 2006 |